Search bioRxiv⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/2022.01.28.478237

On the clinical benefit of on-scalp MEG: A modeling study of on-scalp MEG epileptic activity source estimation ability

Westin, K.·Beniczky, S.·Hamalainen, M.·Lundqvist, D.
View original source ↗Export metadata ↓

Abstract

ObjectiveWhole-head on scalp magnetoencephalography (osMEG) is a novel, cutting-edge functional neuroimaging technique that positions MEG sensors closer to the cortical sources. OsMEG allows both for free head movements and improved spatial resolution compared to conventional MEG. OsMEG thus might improve clinical epilepsy evaluations. However, it remains largely unknown how osMEG characterizes epileptic activity. Here, we aimed to compare epileptic activity source estimation accuracy of osMEG, high-density EEG (hd-EEG), conventional MEG (convMEG) and subdural EEG (sbdEEG). MethodIED and seizure onset zone source estimations of osMEG, hdEEG, convMEG and sbdEEG were evaluated using equivalent current dipoles. Cancellation index of all non-invasive modalities were calculated and compared statistically. To further investigate any similarity between osMEG and sbdEEG, representational similarity analysis was used to compare IED source estimations of these two modalities. ResultsWe found that osMEG IED source estimations were significantly (p<0.05) better than both convMEG and hdEEG. Furthermore, osMEG mesial temporal lobe SOZ source estimations were superior to those of convMEG and hdEEG. OsMEG cancellation index did not differ significantly from convMEG. Interestingly, comparing osMEG and sbdEEG IED source estimation demonstrated that osMEG might be less sensitive to source directions than convMEG. ConclusionWe demonstrated that whole-head osMEG exhibited very accurate non-invasive IED and SOZ source estimations, better than both hd-EEG and convMEG. SignificanceOsMEG has a promising potential to become a safe, highly sensitive neuroimaging modality for whole head epilepsy evaluations. HighlightsO_LIAnalysis of novel on-scalp MEG (osMEG) sensors in epilepsy evaluations C_LIO_LICompares osMEG, EEG, conventional MEG & intracranial EEG epilepsy source estimations C_LIO_LIOur study demonstrates potential great clinical value of osMEG whole-head sensors C_LI

Explore related subjects

neurosciencePreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Westin, K., Beniczky, S., Hamalainen, M., Lundqvist, D.. 2022-01-28. On the clinical benefit of on-scalp MEG: A modeling study of on-scalp MEG epileptic activity source estimation ability. https://doi.org/10.1101/2022.01.28.478237

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

The Unreasonable Effectiveness of Cell Types in Describing Neuronal Physiological Features

Single-cell RNA sequencing (scRNA-seq) captures detailed gene expression profiles at scale, while patch-clamp recordings measure intrinsic neuronal electrophysiological properties. Modeling the relations between these two modalities remains a challenge. Here, we compare how well electrophysiological features can be predicted by traditional transcriptomic cell type classification, representations derived from a foundational model (scGPT) pretrained on large-scale scRNA-seq datasets, ion channel-coding genes, and highly variable genes. Using paired transcriptomic and electrophysiological patch-sequencing data from 495 human neurons from neurosurgical tissue, we find that cluster-level cell type representations consistently outperform highly variable gene selection, ion channel gene selection, and context-enriched scGPT embeddings. Notably, performance varies across model architectures and initializations, and the best results are obtained by combining the outputs of separate cell type and scGPT-based models. Together, these findings suggest that traditional discrete cellular classification is highly effective in predicting physiological features. For maximum performance it can be complemented by pretrained transformer models.

neuroscience↗
bioRxiv2026

A nonlinear inhibition pathway underlying cortical responses to tuned holographic optogenetic perturbations

Optogenetics enables causal manipulation of cortical activity. Perturbation responses can be counterintuitive due to network interactions, making theory essential for predicting them. Existing approaches often rely on linear approximations, which fail for many biologically relevant perturbations. Here we develop a nonlinear theory of responses to holographic perturbations in cell-type-specific recurrent networks with structured connectivity. We fit a nonlinear model to mouse V1 data, which shows cotuned-ensemble suppression: perturbing spatially clustered neurons with similar preferred orientations yields markedly stronger short-range suppression than perturbing untuned ensembles. We show that cotuned-ensemble suppression arises from a feature-tuned, nonlinear inhibition pathway implicating somatostatin-positive (SST) interneurons. The theory predicts that cotuned ensembles suppress parvalbumin-positive (PV) neurons but facilitate SST neurons, and links the degree of cotuned-ensemble suppression or facilitation to the variance of the SST response. This framework identifies mechanisms by which nonlinear inhibition sculpts cortical dynamics and establishes a predictive basis for targeted optogenetic interventions.

neuroscience↗
bioRxiv2026

Proteomic signatures of APOE ε4 across human tissues and cell types in Alzheimers disease

The apolipoprotein E {varepsilon}4 (APOE {varepsilon}4) allele is the strongest genetic risk factor for late-onset Alzheimers disease (AD). However, the underlying molecular mechanisms remain unclear. This study included 1691 participants from the Religious Orders Study and Rush Memory and Aging Project (ROSMAP), 1226 participants from the Accelerating Medicines Partnership - Alzheimers Disease (AMP-AD) Diverse Cohorts Study, and 735 participants from the Alzheimers Disease Neuroimaging Initiative (ADNI). To characterise APOE {varepsilon}4 molecular effects, we analysed proteomic data from plasma, cerebrospinal fluid (CSF), and induced pluripotent stem cell (iPSC)-derived astrocytes and neurons, as well as transcriptomic and proteomic data from multiple brain regions. The association of APOE {varepsilon}4 with AD neuropathology was also examined. APOE {varepsilon}4 carriers shared a plasma proteomic signature enriched for immune processes, irrespective of AD diagnosis. A machine learning classifier trained on this signature discriminated APOE {varepsilon}4 carriers from non-carriers in an independent cohort using CSF proteomics. APOE {varepsilon}4 carriage was associated with higher Braak stages and Consortium to Establish a Registry for Alzheimers Disease (CERAD) score. However, only limited APOE {varepsilon}4-associated transcriptomic and proteomic changes were observed in bulk brain tissue, with poor cross-layer concordance. Proteomic analyses of iPSC-derived astrocytes and neurons further revealed cell-type-specific APOE {varepsilon}4-associated changes. APOE {varepsilon}4 is associated with a consistent proteomic signature across plasma and CSF. Its molecular effects in the brain differ across cell types, brain regions and molecular layers. These findings support the need for cell-type-resolved multi-omic studies to elucidate how APOE {varepsilon}4 confers AD risk.

neuroscience↗